Virus Expression Database

GSE102203

Expression data from EBV+ and EBV- plasmablastic lymphomas

Submitted by Pauline Gravelle (IUCT-ONCOPOLE, France) on Aug 03 2017

Platform: microarray – [HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [probe set (exon) version]

Pubmed: None listed

Summary We produced and analyzed the transcriptomic profiles of agressive plasmablastic lymphomas to describe their "immune escape" profile, depending on their viral status (HIV, EBV, ...). We used microarrays to compare the global gene expression profile between EBV+ and EBV- PL subtypes. This analysis unveiled the interest of treating EBV+ PL patients by immune checkpoint blockade strategies.
Plasmablastic lymphoma (PL) is a subtype of diffuse large B-cell lymphoma occurring frequently in HIV-positive individuals and most often associated with Epstein Barr Virus infection. Despite recent therapeutic progress, PL still is an aggressive lymphoma with adverse prognosis. The aim of this study was to investigate whether the emerging strategies of immune checkpoint blockade could be efficient for PL patients. Here, we produced and analyzed the transcriptomic profiles of such tumors to address this question. Unsupervised hierarchical analysis of PL samples showed that PL segregated according to their EBV-status. Moreover, we report that EBV+ PL displayed a significant association with abundant leucocyte infiltrate and selective T-cell activation signatures, together with high level of inhibitory receptors and immune checkpoint markers. We propose that EBV infection induced an anti-viral cytotoxic immunity which progressively exhausted and promoted the tolerogenic tumor microenvironment of PL. Hence, most EBV+ PL patients presenting an early stage of cancer immune-editing process appear eligible for ICB immunotherapies.

9 Samples

ID Title Cell Type Timepoint Reported Virus Virus Species Exclusion Reason
GSM2730278 Patient_10P6274_EBV- plasmablastic lymphoma cell  EBV- Uninfected Data failed QC
pm_mean is 63.940301 (low signal, below threshold of 60)
all_probeset_mad_residual_mean is 1.004244 (poor normalization, above threshold of 0.80)
GSM2730279 Patient_14P5581_EBV+ plasmablastic lymphoma cell  persistent EBV+ Human gammaherpesvirus 4 Data failed QC
all_probeset_mad_residual_mean is 0.812318 (poor normalization, above threshold of 0.80)
GSM2730280 Patient_14P11149_EBV+ plasmablastic lymphoma cell  persistent EBV+ Human gammaherpesvirus 4 Data failed QC
all_probeset_mad_residual_mean is 0.943093 (poor normalization, above threshold of 0.80)
GSM2730281 Patient_12P12002_EBV+ plasmablastic lymphoma cell  persistent EBV+ Human gammaherpesvirus 4 Data failed QC
all_probeset_mad_residual_mean is 0.911122 (poor normalization, above threshold of 0.80)
GSM2730282 Patient_P14.290_EBV- plasmablastic lymphoma cell  EBV- Uninfected Data failed QC
At least 40% of samples in study failed QC
GSM2730283 Patient_14P11667_EBV+ plasmablastic lymphoma cell  persistent EBV+ Human gammaherpesvirus 4 Data failed QC
all_probeset_mad_residual_mean is 0.859295 (poor normalization, above threshold of 0.80)
GSM2730284 Patient_14P11148_EBV- plasmablastic lymphoma cell  EBV- Uninfected Data failed QC
all_probeset_mad_residual_mean is 0.853151 (poor normalization, above threshold of 0.80)
GSM2730285 Patient_14T8922_EBV+ plasmablastic lymphoma cell  persistent EBV+ Human gammaherpesvirus 4 Data failed QC
all_probeset_mad_residual_mean is 0.960167 (poor normalization, above threshold of 0.80)
GSM2730286 Patient_14T17450_EBV+ plasmablastic lymphoma cell  persistent EBV+ Human gammaherpesvirus 4 Data failed QC
At least 40% of samples in study failed QC